Experts from Philip Morris (PM) yesterday presented scientific evidence to the FDA Tobacco Products Scientific Advisory Committee, or TPSAC, as part of the FDA’s process for a modified risk tobacco product designation for their Zyn nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching completely to ZYN reduces their risk of many smoking-related diseases.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PM:
- N.Y. Governor plans to tax ZYN pouches at rate as cigarettes, NY Post says
- Midday Fly By: Netflix and Warner amend deal, GSK to acquire Rapt
- Philip Morris downgraded to Hold from Buy at Jefferies
- Philip Morris: Strong Fundamentals but Growing Competitive and Regulatory Headwinds Justify Hold Rating
- Philip Morris boosts U.S. smoke-free investments and jobs